

Oncology Today with Dr Neil Love: Novel Agents Under Investigation in Multiple Myeloma (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What is the target of the various chimeric antigen receptor (CAR) T-cell platforms under evaluation for patients with multiple myeloma (MM)?
 - a. CD19
 - b. B-cell maturation antigen (BCMA)
 - c. CD20
2. The ongoing Phase III OCEAN trial is evaluating which of the following agents in combination with dexamethasone versus pomalidomide/dexamethasone for patients with relapsed/refractory MM?
 - a. Belantamab mafodotin
 - b. Iberdomide
 - c. Idecabtagene vicleucel
 - d. Melflufen
3. What was observed with regard to the activity and adverse-event profile of the recently FDA-approved anti-BCMA antibody-drug conjugate belantamab mafodotin in the Phase II DREAMM-2 study for patients with heavily pretreated MM?
 - a. Unacceptably high rates of Grade 5 adverse events
 - b. A low overall response rate (<20%)
 - c. Frequent ocular toxicities
4. In the Phase III BELLINI trial, which demonstrated a significant improvement in progression-free survival with the addition of venetoclax to bortezomib/dexamethasone for patients with relapsed/refractory MM both in the overall study population and in the subset of patients with t(11;14) mutations, what was observed in terms of overall survival with the addition of venetoclax?
 - a. Significant improvement in the overall study population but not in the subset of patients with t(11;14) mutations
 - b. Significant improvement for patients with t(11;14) mutations
 - c. Significant improvement for patients without t(11;14) mutations